Figure 1
Blockade of CD132 reduces acute GVHD. (A) Survival of transplanted mice receiving isotype control IgG (30 mg/kg) or anti-CD132 (30mg/kg) mAb from day −1 to +15, 3 times per week. The anti-CD132 mAb-treated group lived longer than the isotype-treated group (P < .0001). (B) Seven days after allo-HCT, mice from the indicated groups were sacrificed and the small intestine, large intestine, and liver were analyzed for histological signs of GVHD according to a published15 scoring system (**P < .01). (C) Serum was collected on day 7 after allo-HCT and analyzed for the indicated cytokines. Data are pooled from 2 experiments, representing 12 animals per group (*P < .05, **P < .01, ***P < .001).

Blockade of CD132 reduces acute GVHD. (A) Survival of transplanted mice receiving isotype control IgG (30 mg/kg) or anti-CD132 (30mg/kg) mAb from day −1 to +15, 3 times per week. The anti-CD132 mAb-treated group lived longer than the isotype-treated group (P < .0001). (B) Seven days after allo-HCT, mice from the indicated groups were sacrificed and the small intestine, large intestine, and liver were analyzed for histological signs of GVHD according to a published15  scoring system (**P < .01). (C) Serum was collected on day 7 after allo-HCT and analyzed for the indicated cytokines. Data are pooled from 2 experiments, representing 12 animals per group (*P < .05, **P < .01, ***P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal